Research & Education

A primary goal of the Institute is to identify or discover agents or modalities that act specifically to initiate healing, and then make these results available in venues such as professional and lay publications and conferences. Toward this end, we are interested in examining the underlying, sub-molecular processes that regulate homeodynamics. One avenue of inquiry relates to investigating diseases which, to us, reflect disregulation of the immune, nervous, or endocrine systems, or malfunction at the individual cell level. Better understanding and management of the regulatory systems also offers a path to quickening our knowledge of endogenous processes of health and healing.

Initial research pertaining to regulatory systems led to the Resonant Molecular Signaling (RMS) platform, a therapeutic approach that typically uses naturally-occurring molecules at physiological concentrations to induce specific cells to carry out their normal function. The range of indications addressed by RMS highlights the viability of this approach to healing which is revealing heretofore unknown processes of how the body works. Scientists at the University of North Carolina at Chapel Hill, for example, have confirmed that the RMS anti-depressant works via different biopathways than current pharmaceuticals that address depression. As a result, the success already found in this manner of cellular communication has established new research pathways. Institute investigators are now targeting the nature of the signals associated with the molecules rather than the actions of the molecules themselves. The energetic changes reflecting differences between pathology and health are therefore one area of exploration. Examining the effects of sound and light on genomic expression is also of interest. An overarching goal is determining the relationships among these various therapeutic modalities and homeodynamics.

This research is not without firm footing. Clinicians and scientists associated with the Institute started on this path by looking at aberrant immune responses and how these relate to allergy, and then they focused on how to control these responses. This work continues with our advances in understanding how the cross-reactive properties of one substance, such as mesquite, can be applied to neutralizing allergic reactions from a range of seemingly unrelated substances. This work has been published in peer-reviewed journals, and in the popular press.1-4

Based on these allergy studies, the next stage was determining how to control regulatory cells in the body by the use of specific molecules in order to address a spectrum of chronic disorders. This effort led to numerous patents and FDA-authorized Phase 2 clinical trials targeting diseases such as multiple sclerosis, chronic fatigue syndrome, benign prostatic hyperplasia, a variety of respiratory disorders, and cancer and cancer-associated pain.

Research then centered on examining fractions of molecules as a means to control regulatory functions. This was first accomplished and explained by relating data to classic biochemical pathways and then later to signal transduction models. To date, for example, three successful FDA-authorized clinical trials focusing on chronic bronchitis, chronic obstructive pulmonary disease (COPD), and cystic fibrosis documented the safety and efficacy regarding the use of micro-dose DNA to address respiratory disorders. A peer-reviewed paper and lay article about this formulation have been published. This formulation has been out-licensed and is currently marketed as a nutraceutical under the trade name Mucolyxirâ„¢.5-6 Clinicians affiliated with the Institute have also found this product to be highly effective for addressing otitis media, middle ear inflammation experienced by 75 percent of children before their third year.7

As laboratory, animal, and human data pertaining to a spectrum of RMS agents accumulated, it became evident that RMS dosages act independent of mass and are rapidly transmitted throughout the entire body. A small dog, a human, or an elephant could receive the same dose with equal results. This clearly separates RMS from other therapeutic approaches. Questions therefore arise: what kind of signal is initiated by a RMS agent? and what is the nature of the reception of the signal?

To find answers, a review of literature from a variety of disciplines coupled with on-going laboratory and clinical evaluation set the stage to devote resources to investigate other, not yet fully articulated, communication systems of the body such as those in and of the extracellular matrix, a latticework that binds parts of the body into a whole. This interconnectedness is essential to understanding the role of energetics in health and disease.8 Accordingly, understanding energetic mechanisms of signaling such as biophotonic activity and/or sound waves may yield knowledge of how to harness the body's natural healing abilities.